Tumor Biology

, Volume 37, Issue 1, pp 1197–1204 | Cite as

MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2

  • Jing Xie
  • Fei Yu
  • Dan Li
  • Xuchao Zhu
  • Xiaoping Zhang
  • Zhongwei Lv
Original Article


Downregulation of microRNA-218 (miR-218) is found in various human cancers, including non-small cell lung cancer (NSCLC). However, the involvement of chemosensitivity to cisplatin (DDP) and the underlying molecular mechanism remain unclear. In this study, we investigate whether miR-218 mediates NSCLC cell functions associated with chemoresistance. Quantitative real-time polymerase chain reaction (qRT-PCR) was utilized to detect miR-218 expression in NSCLC cell lines A549/DDP and/or A549. The cell activity was measured by MTT assay. Cell cycle and cell apoptosis were detected by flow cytometry. Luciferase reporter assays and Western blots were used to validate runt-related transcription factor 2 (RUNX2) as a direct target gene of miR-218. miR-218 was significantly reduced in A549/DDP cells compared with parent A549 cells. Upregulation of miR-218 altered cell cycle-induced cell apoptosis and enhanced the sensitivity of A549/DDP cells to cisplatin. Mechanistically, RUNX2 was identified as a direct and functional target of miR-218, and RUNX2 executed the former on lung cancer chemoresistance. Our present study demonstrated for the first time that downregulation of miR-218 may contribute to the chemoresistance of NSCLC cells to cisplatin, which leads to upregulation of RUNX2. Uncovering the mechanism represents a novel approach to enhance the efficacy of chemotherapy during cancer treatment.


miR-218 RUNX2 Cisplatin (DDP) Chemosensitivity NSCLC 



This study was supported by the health system advanced appropriate technology promotion project of Shanghai in China (2013SY036).

Conflicts of interest

The authors declare that there are no conflicts of interest.

Authors’ contributions

JX, FY, and LZW conceived and designed the experiments. JX and ZXC performed the experiments. JX, DL, and FY analyzed the data. ZW and ZXC contributed the reagents/materials/analysis tools. JX wrote the paper. LZW and ZXC reviewed the manuscript.


  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin. 2014;64:9–29.Google Scholar
  2. 2.
    Soria JC, Kim ES, Fayette J, Lantuejoul S, Deutsch E, Hong WK. Chemoprevention of lung cancer. Lancet Oncol. 2003;4:659–69.CrossRefPubMedGoogle Scholar
  3. 3.
    Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–34.CrossRefPubMedGoogle Scholar
  4. 4.
    Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5.CrossRefPubMedGoogle Scholar
  5. 5.
    van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer. 2011;11:644–56.CrossRefPubMedGoogle Scholar
  6. 6.
    Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009;113:249–55.CrossRefPubMedGoogle Scholar
  8. 8.
    Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 2008;7:1–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007;31:277–83.PubMedGoogle Scholar
  10. 10.
    Song L, Huang Q, Chen K, Liu L, Lin C, Dai T, et al. miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-beta. Biochem Biophys Res Commun. 2010;402:135–40.CrossRefPubMedGoogle Scholar
  11. 11.
    Tatarano S, Chiyomaru T, Kawakami K, Enokida H, Yoshino H, Hidaka H, et al. miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. Int J Oncol. 2011;39:13–21.PubMedGoogle Scholar
  12. 12.
    Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, et al. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 2011;71:5765–78.CrossRefPubMedGoogle Scholar
  13. 13.
    Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene. 2008;27:2575–82.CrossRefPubMedGoogle Scholar
  14. 14.
    Davidson MR, Larsen JE, Yang IA, Hayward NK, Clarke BE, Duhig EE, et al. MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. PLoS One. 2010;5:e12560.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Venkataraman S, Birks DK, Balakrishnan I, Alimova I, Harris PS, Patel PR, et al. MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma. J Biol Chem. 2013;288:1918–28.CrossRefPubMedGoogle Scholar
  16. 16.
    Yamamoto N, Kinoshita T, Nohata N, Itesako T, Yoshino H, Enokida H, et al. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. Int J Oncol. 2013;42:1523–32.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Li J, Ping Z, Ning H. MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer. Int J Mol Sci. 2012;13:16053–64.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Tian H, Hou L, Xiong YM, Huang JX, She YJ, Bi XB, et al. miR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin. Oncol Rep. 2015;33:981–9.PubMedGoogle Scholar
  19. 19.
    Panchuk R, Skorokhyd N, Chumak V, Lehka L, Omelyanchik S, Gurinovich V, et al. Specific antioxidant compounds differentially modulate cytotoxic activity of doxorubicin and cisplatin: in vitro and in vivo study. Croatian Medical J. 2014;55:206–17.CrossRefGoogle Scholar
  20. 20.
    Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 2011;71:3–10.CrossRefPubMedGoogle Scholar
  21. 21.
    Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol : Off J Am Soc Clin Oncol. 2009;27:5848–56.CrossRefGoogle Scholar
  22. 22.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMedGoogle Scholar
  23. 23.
    Lee SH, Che X, Jeong JH, Choi JY, Lee YJ, Lee YH, et al. Runx2 protein stabilizes hypoxia-inducible factor-1alpha through competition with von Hippel-Lindau protein (pVHL) and stimulates angiogenesis in growth plate hypertrophic chondrocytes. J Biol Chem. 2012;287:14760–71.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Browne G, Nesbitt H, Ming L, Stein GS, Lian JB, McKeown SR, et al. Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance. Br J Cancer. 2012;107:1714–21.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Goloudina AR, Tanoue K, Hammann A, Fourmaux E, Le Guezennec X, Bulavin DV, et al. Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents. Proc Natl Acad Sci U S A. 2012;109:E68–75.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Nuclear, Shanghai Tenth People’s HospitalTongji University, School of MedicineShanghaiChina

Personalised recommendations